PMID- 32260373
OWN - NLM
STAT- MEDLINE
DCOM- 20210302
LR  - 20240328
IS  - 2072-6651 (Electronic)
IS  - 2072-6651 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Apr 4
TI  - Inflammation and Premature Ageing in Chronic Kidney Disease.
LID - 10.3390/toxins12040227 [doi]
LID - 227
AB  - Persistent low-grade inflammation and premature ageing are hallmarks of the 
      uremic phenotype and contribute to impaired health status, reduced quality of 
      life, and premature mortality in chronic kidney disease (CKD). Because there is a 
      huge global burden of disease due to CKD, treatment strategies targeting 
      inflammation and premature ageing in CKD are of particular interest. Several 
      distinct features of the uremic phenotype may represent potential treatment 
      options to attenuate the risk of progression and poor outcome in CKD. The nuclear 
      factor erythroid 2-related factor 2 (NRF2)-kelch-like erythroid cell-derived 
      protein with CNC homology [ECH]-associated protein 1 (KEAP1) signaling pathway, 
      the endocrine phosphate-fibroblast growth factor-23-klotho axis, increased 
      cellular senescence, and impaired mitochondrial biogenesis are currently the most 
      promising candidates, and different pharmaceutical compounds are already under 
      evaluation. If studies in humans show beneficial effects, carefully phenotyped 
      patients with CKD can benefit from them.
FAU - Ebert, Thomas
AU  - Ebert T
AUID- ORCID: 0000-0003-1683-9276
AD  - Karolinska Institutet, Department of Clinical Science, Intervention and 
      Technology, Division of Renal Medicine, SE-141 86 Stockholm, Sweden.
FAU - Pawelzik, Sven-Christian
AU  - Pawelzik SC
AD  - Karolinska Institutet, Department of Medicine Solna, Cardiovascular Medicine 
      Unit, SE-171 76 Stockholm, Sweden.
AD  - Karolinska University Hospital, Theme Heart and Vessels, Division of Valvular and 
      Coronary Disease, SE-171 76 Stockholm, Sweden.
FAU - Witasp, Anna
AU  - Witasp A
AD  - Karolinska Institutet, Department of Clinical Science, Intervention and 
      Technology, Division of Renal Medicine, SE-141 86 Stockholm, Sweden.
FAU - Arefin, Samsul
AU  - Arefin S
AD  - Karolinska Institutet, Department of Clinical Science, Intervention and 
      Technology, Division of Renal Medicine, SE-141 86 Stockholm, Sweden.
FAU - Hobson, Sam
AU  - Hobson S
AD  - Karolinska Institutet, Department of Clinical Science, Intervention and 
      Technology, Division of Renal Medicine, SE-141 86 Stockholm, Sweden.
FAU - Kublickiene, Karolina
AU  - Kublickiene K
AD  - Karolinska Institutet, Department of Clinical Science, Intervention and 
      Technology, Division of Renal Medicine, SE-141 86 Stockholm, Sweden.
FAU - Shiels, Paul G
AU  - Shiels PG
AD  - University of Glasgow, Wolfson Wohl Cancer Research Centre, College of Medical, 
      Veterinary & Life Sciences, Institute of Cancer Sciences, Glasgow G61 1QH, UK.
FAU - Back, Magnus
AU  - Back M
AUID- ORCID: 0000-0003-0853-5141
AD  - Karolinska Institutet, Department of Medicine Solna, Cardiovascular Medicine 
      Unit, SE-171 76 Stockholm, Sweden.
AD  - Karolinska University Hospital, Theme Heart and Vessels, Division of Valvular and 
      Coronary Disease, SE-171 76 Stockholm, Sweden.
FAU - Stenvinkel, Peter
AU  - Stenvinkel P
AD  - Karolinska Institutet, Department of Clinical Science, Intervention and 
      Technology, Division of Renal Medicine, SE-141 86 Stockholm, Sweden.
LA  - eng
GR  - Novo Nordisk postdoctoral fellowship run in partnership with Karolinska 
      Institutet, Stockholm, Sweden/Novo Nordisk/International
GR  - 20180571 and 20160384/Swedish Heart and Lung Foundation/International
GR  - N/A/King Gustaf V and Queen Victoria Freemason Foundation/International
GR  - N/A/Professor Nanna Svartz Foundation/International
GR  - 20170365/Stockholms Lans Landsting/International
GR  - (Swedish Kidney Foundation)/Njurfonden/International
GR  - 2009-1068/Vetenskapsradet/International
GR  - 2018-00932/Vetenskapsradet/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200404
PL  - Switzerland
TA  - Toxins (Basel)
JT  - Toxins
JID - 101530765
RN  - 0 (Biomarkers)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Toxins, Biological)
SB  - IM
MH  - Aging, Premature/*metabolism/mortality/physiopathology
MH  - Animals
MH  - Biomarkers/metabolism
MH  - Health Status
MH  - Humans
MH  - Inflammation/*metabolism/mortality/physiopathology/therapy
MH  - Inflammation Mediators/*metabolism
MH  - Kidney/*metabolism/pathology/physiopathology
MH  - Phenotype
MH  - Prognosis
MH  - Quality of Life
MH  - Renal Insufficiency, Chronic/*metabolism/mortality/physiopathology/therapy
MH  - Risk Factors
MH  - Signal Transduction
MH  - Toxins, Biological/*metabolism
MH  - Uremia/*metabolism/mortality/physiopathology/therapy
PMC - PMC7232447
OTO - NOTNLM
OT  - ageing
OT  - chronic kidney disease
OT  - end-stage kidney disease
OT  - inflammation
OT  - premature ageing
OT  - senescence
OT  - uremic toxins
COIS- Peter Stenvinkel serves on scientific advisory boards of Baxter, Reata, and Astra 
      Zeneca. The other authors of this manuscript have nothing to declare.
EDAT- 2020/04/09 06:00
MHDA- 2021/03/03 06:00
PMCR- 2020/04/01
CRDT- 2020/04/09 06:00
PHST- 2020/02/01 00:00 [received]
PHST- 2020/03/20 00:00 [revised]
PHST- 2020/03/29 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/03/03 06:00 [medline]
PHST- 2020/04/01 00:00 [pmc-release]
AID - toxins12040227 [pii]
AID - toxins-12-00227 [pii]
AID - 10.3390/toxins12040227 [doi]
PST - epublish
SO  - Toxins (Basel). 2020 Apr 4;12(4):227. doi: 10.3390/toxins12040227.